Head And Neck Cancer Therapeutics Market Size, Share, Growth, Trends | Report 2023-2032
The global head and neck cancer therapeutics market size was estimated at around USD 1.37 billion in 2022 and it is projected to hit around USD 4.48 billion by 2032, growing at a CAGR of 12.56% from 2023 to 2032.
Key Pointers
| Report Coverage | Details |
| Market Size in 2022 | USD 1.37 billion |
| Revenue Forecast by 2032 | USD 4.48 billion |
| Growth rate from 2023 to 2032 | CAGR of 12.56% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Eli Lilly and Company; Sanofi; Merck & Co., Inc.; Clinigen Group plc.; Bristol-Myers Squibb Company; AstraZeneca; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd; F. Hoffmann-La Roche Ltd. |
The increasing prevalence of head and neck cancer is anticipated to fuel market growth. According to the American Society of Clinical Oncology (ASCO) in the U.S., approximately 4% of all cancer cases are related to the head and neck. It is estimated that around 66,470 people including 48,520 men and 17,950 women were diagnosed with this disease in 2022. Head and neck cancer patients are potentially at high risk of exposure to SARS-CoV-2 infections as they require frequent outpatient visits to assess disease progression and the use of systemic drug therapies to control serious disease conditions.
According to National Center for Biotechnology Information, nonsurgical therapies were the most preferred treatment option for HNC patients by physicians instead of surgical treatment being first-line treatment due to COVID-19-specific multilevel risks to HNC patients. Therefore, demand for nonsurgical therapeutics such as chemotherapy, immunosuppressive, and targeted therapy increased during the COVID-19 pandemic.
The presence of a strong product pipeline and their expected launch will contribute to market growth. Some of the products in the pipeline are Tipifarnib (Farnesyltransferase Inhibitor), tiragolumab (anti-TIGIT), Tecentriq (atezolizumab), Rozlytrek (entrectinib), and Afatinib. Successful completion of trials and subsequent approval is anticipated to drive market growth over the forecast period. In February 2021, the U.S. FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug.
Head And Neck Cancer Therapeutics Market Segmentations:
| By Therapy Type | By Route of Administration | By Channel |
|
Chemotherapy Immunotherapy Targeted Therapy |
Injectable Oral |
Retail & Specialty Pharmacies Hospital Pharmacies Online Pharmacies |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Head And Neck Cancer Therapeutics Market
5.1. COVID-19 Landscape: Head And Neck Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Head And Neck Cancer Therapeutics Market, By Therapy Type
8.1. Head And Neck Cancer Therapeutics Market, by Therapy Type, 2023-2032
8.1.1 Chemotherapy
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Targeted Therapy
8.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Head And Neck Cancer Therapeutics Market, By Route of Administration
9.1. Head And Neck Cancer Therapeutics Market, by Route of Administration, 2023-2032
9.1.1. Injectable
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Head And Neck Cancer Therapeutics Market, By Channel
10.1. Head And Neck Cancer Therapeutics Market, by Channel, 2023-2032
10.1.1. Retail & Specialty Pharmacies
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Hospital Pharmacies
10.1.2.1. Market Revenue and Forecast (2019-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 11. Global Head And Neck Cancer Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.1.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.1.3. Market Revenue and Forecast, by Channel (2019-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.1.4.3. Market Revenue and Forecast, by Channel (2019-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.1.5.3. Market Revenue and Forecast, by Channel (2019-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.2.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.2.3. Market Revenue and Forecast, by Channel (2019-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.2.4.3. Market Revenue and Forecast, by Channel (2019-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.2.5.3. Market Revenue and Forecast, by Channel (2019-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.2.6.3. Market Revenue and Forecast, by Channel (2019-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.2.7.3. Market Revenue and Forecast, by Channel (2019-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.3.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.3.3. Market Revenue and Forecast, by Channel (2019-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.3.4.3. Market Revenue and Forecast, by Channel (2019-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.3.5.3. Market Revenue and Forecast, by Channel (2019-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.3.6.3. Market Revenue and Forecast, by Channel (2019-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.3.7.3. Market Revenue and Forecast, by Channel (2019-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.4.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.4.3. Market Revenue and Forecast, by Channel (2019-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.4.4.3. Market Revenue and Forecast, by Channel (2019-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.4.5.3. Market Revenue and Forecast, by Channel (2019-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.4.6.3. Market Revenue and Forecast, by Channel (2019-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.4.7.3. Market Revenue and Forecast, by Channel (2019-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.5.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.5.3. Market Revenue and Forecast, by Channel (2019-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.5.4.3. Market Revenue and Forecast, by Channel (2019-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapy Type (2019-2032)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2019-2032)
11.5.5.3. Market Revenue and Forecast, by Channel (2019-2032)
Chapter 12. Company Profiles
12.1. Eli Lilly and Company
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co., Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Clinigen Group plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bristol-Myers Squibb Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AstraZeneca
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Takeda Pharmaceutical Company Limited
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Teva Pharmaceutical Industries Ltd
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. F. Hoffmann-La Roche Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers